Molecular self-assembly of a tyroservatide-derived octapeptide and hydroxycamptothecin for enhanced therapeutic efficacy
- 9 February 2021
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 13 (9) , 5094-5102
Abstract
Tyroservatide (YSV) belongs to a class of bioactive peptides that have drawn considerable attention in the field of drug discovery, yet it displays limited potency and often requires a millimolar concentration to execute its cellular functions. To enhance the potency of the drug through a self-assembling strategy, we designed and synthesized a series of octapeptides through conjugation of YSV with a pentapeptide sequence bearing alternating hydrophobic and hydrophilic amino acids to promote their self-assembling capabilities. Initial screening for hydrogelation gave a novel octapeptide (denoted as 1-YSV hereafter) that was capable of self-assembling under physiological conditions to afford supramolecular nanofibers with enhanced anti-cancer efficacy compared to YSV itself. Interestingly, 1-YSV formed a robust co-assembly with the anticancer drug hydroxycamptothecin (HCPT) to afford 1-YSV/HCPT hydrogel, which not only greatly improved the viscoelastic properties of hydrogels, but also stabilized HCPT in the hydrogel matrix and avoided the agglomeration of drug molecules. Compared to HCPT solution, the hydrogel formulation of 1-YSV/HCPT demonstrated better efficacy against the proliferation of non-small cell lung cancer A549 cells both in vitro and in vivo. Finally, thanks to the pure amino acid-based composition, the 1-YSV/HCPT formulation exhibited excellent biocompatibility, giving a low hemolytic rate to red blood cells, with mild local tissue reactions and negligible systematic toxicities in mice.Keywords
Funding Information
- National Natural Science Foundation of China (51973234)
- National Natural Science Foundation of China (21775165)
- Natural Science Foundation of Jiangsu Province (BK20191326)
- Double First Class University Plan (CPU 2018GY25)
This publication has 33 references indexed in Scilit:
- Preorganization Increases the Self-Assembling Ability and Antitumor Efficacy of Peptide NanomedicineACS Applied Materials & Interfaces, 2020
- Enhanced cellular uptake and nuclear accumulation of drug-peptide nanomedicines prepared by enzyme-instructed self-assemblyJournal of Controlled Release, 2020
- Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining ChallengesJournal of the American Chemical Society, 2019
- Anticancer Supramolecular Hydrogel of D/L-Peptide with Enhanced Stability and BioactivityJournal of Biomedical Nanotechnology, 2018
- Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to PatientsCurrent Medicinal Chemistry, 2016
- Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative reviewBritish Journal of Pharmacology, 2016
- Effects of tyroservatide on histone acetylation in lung carcinoma cellsInternational Journal of Cancer, 2010
- The antiangiogenic effects of tyroservatide on animal models of hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2009
- Tyroservatide Therapy for Tumor Growth, Invasion and Metastasis of Lewis Lung Carcinoma and Human Lung Carcinoma A549Oncology, 2006
- Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV)International Journal of Cancer, 2005